生物制药市场基于(关键地区、市场参与者、规模和份额)- 到 2031 年的预测

  • Report Code : TIPRE00029847
  • Category : Biotechnology
  • Status : Published
  • No. of Pages : 346
Buy Now

[研究报告]生物制药市场预计将从2022年的329,966.22百万美元增长到2028年的7,00,873.94百万美元;预计 2022 年至 2028 年复合年增长率为 13.4%。

癌症治疗应用的增加和治疗罕见疾病的潜力是推动生物制药市场增长的一些因素。

< p>根据美国国家癌症研究所的报告,癌症是全球主要死亡原因之一。例如,2018 年,全球新增癌症病例 1810 万例,癌症相关死亡人数 950 万。到 2040 年,新发癌症病例预计将增加到 2950 万,癌症相关死亡人数将增加到 1640 万。美国卫生与公共服务部的报告指出,每年每 10 万名男性和女性中有 52 例肺癌和支气管癌新发病例。预计2022年肺癌和支气管癌新发病例数为236,740例,占所有癌症新发病例的12.3%。生物制药为控制如此高的癌症发病率提供了新的机会。通过了解潜在的生物学机制和患者免疫系统在抗击癌症中的作用,生物制药研究人员正在生产用于治疗不同类型癌症的新药。这些范围从 CAR-T 细胞疗法到免疫检查点抑制剂和个性化药物,针对导致特定癌症疾病的遗传缺陷。美国药物研究和制造商 (PhRMA) 的一份报告显示,美国食品和药物管理局 (FDA) 已批准六种 CAR-T 疗法用于治疗多种癌症类型,包括儿童癌症病例。此外,PhRMA 报告显示其他治疗方法,例如具有转化多种癌症潜力的 mRNA,已获得批准。例如,2023 年 2 月,美国 FDA 认可 mRNA-4157/V940(Moderna, Inc. 和默克公司生产的一种在研个性化 mRNA 癌症疫苗)与 KEYTRUDA 联合使用为突破性疗法。此外,超过 1,300 种治疗各种癌症的药物和疫苗目前正在进行临床试验或等待 FDA 批准。其中包括免疫疗法(单克隆抗体和 CAR-T)、靶向癌症基因编辑、溶瘤病毒疗法以及针对特定癌细胞而不伤害正常细胞的抗体药物偶联物 (ADC)。

< p>< em >来源:PhRMA 癌症药物开发,2020 年 12 月

因此,全球癌症发病率不断上升,产生了对安全、有效和高效诊断的需求。

战略信息

应用细分信息

根据应用,生物制药市场分为肿瘤、炎症和生物制药。传染病、自身免疫性疾病、代谢紊乱、荷尔蒙紊乱和生长障碍疾病、心血管疾病、神经系统疾病等。肿瘤学领域在 2022 年占据最大的市场份额。然而,炎症和传染病领域预计在预测期内将创下最高复合年增长率。根据美国国立卫生研究院(NIH)的报告,癌症是一种复杂的侵袭性遗传疾病,在全世界范围内导致大量死亡。例如,基于蛋白质的生物制药已显着延长了数百万癌症患者的生命。此外,几家大公司已开展研究合作,开发基于蛋白质的新型技术,用于癌症治疗。例如,2022年4月,Ubix Therapeutics宣布与SK Biopharmaceuticals合作,通过Ubix的Degradducer技术开发用于治疗癌症的新化合物和药物。上述因素推动了该细分市场的增长,从而促进了预测期内生物制药市场的增长。

北美在预测期内可能会继续在生物制药市场占据主导地位期. 预测期. 2022年,美国在该地区拥有最大的市场份额。根据国际贸易管理局的报告,美国是最大的生物制药市场,约占全球生物制药市场的三分之一,是生物制药研发的先驱。此外,生物制药行业对美国经济的影响也是巨大的。 2018年,超过170亿美元的生物制药出口来自大多数在美国经营的外资公司。此外,同年,这些外资占多数的公司在研发上花费了约 200 亿美元。

另一方面,亚太地区预计在此期间将出现利润丰厚的增长。这是因为中国的生物制药行业正在经历巨大转变,从以仿制药为中心转变为蓬勃发展的创新中心。此外,工业化的推进以及新药和高端医疗器械及技术的不断应用是中国生物制药市场增长的一些因素。根据创新基金会(ITIF)的报告,中国在创新方面取得了长足进步,可以与美国媲美。此外,迄今为止,中国以平均36项指标与美国的差距缩小了1.5个竞争因子(竞争因子是根据其在实现公司战略目标中的相对重要性来识别和评估的)。此外,十年前,中国落后美国80%;然而,由于创新的巨大进步、技术的涌入以及国家主导的有利的工业和贸易政策,到 2022 年,这一数字将达到 50%。此外,治疗罕见疾病的新产品的批准进一步影响了中国的市场增长。例如,2022年3月,中国领先的生物制药公司北海康成制药有限公司宣布,台湾食品药品监督管理局(TFDA)已接受“CAN108 [ maralixibat 口服溶液 (LIVMARLI TM)]”旨在治疗 1 岁或以上 Alagille 综合征 (ALGS) 患者的胆汁淤积性瘙痒。

生物制药市场利润丰厚的区域

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What are biopharmaceuticals?

Biopharmaceuticals are complex medicines that are manufactured by extracting proteins and nucleic acids directly from biological sources using biotechnology. Most biopharmaceuticals are pharmaceutical products that are made from living organisms; transgenic organisms are genetically modified plants and animals, and this process is used to produce biopharmaceuticals; nevertheless, it is a controversial technology still in the testing phase.

What are the driving factors for the biopharmaceuticals market across the globe?

Key factors that are driving the growth of this market are rising application in cancer therapeutics and potential to treat rare diseases are expected to boost the market growth for the biopharmaceuticals over the years.

What is the market CAGR value of biopharmaceuticals market during forecast period?

The CAGR value of the biopharmaceuticals market during the forecasted period of 2022-2028 is 13.4%.

Which product type leads the biopharmaceuticals market?

The monoclonal antibodies segment held the largest share of the market in the global biopharmaceuticals market and held the market share of 48.42% in 2022.

Who are the key players in the biopharmaceuticals market?

The biopharmaceuticals market majorly consists of the players such Amgen Inc, AbbVie Inc, Eli Lilly and Co, Bristol-Myers Squibb Co, Johnson & Johnson, Thermo Fisher Scientific Inc, AGC Biologics AS, Lonza Group AG, WuXi Biologics Inc, Boehringer Ingelheim International GmbH amongst others.

Which are the top companies that hold the market share in biopharmaceuticals market?

Eli Lilly and Co and Amgen Inc are the top two companies that hold huge market shares in the biopharmaceuticals market.

Which region is expected to witness significant demand for biopharmaceuticals market in the coming years?

Global biopharmaceuticals market is segmented by region into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America held the largest market share of the biopharmaceuticals market in 2022. With several North American market players focusing on research and development activities in the field of imaging technology, the regional market for biopharmaceuticals market is likely to propel in North America region during the forecast period.

The List of Companies - Biopharmaceuticals Market

  1. Amgen Inc.
  2. AbbVie Inc.
  3. Eli Lilly and Co
  4. Bristol-Myers Squibb Co
  5. Johnson & Johnson
  6. Thermo Fisher Scientific Inc
  7. AGC Biologics AS
  8. Lonza Group AG
  9. WuXi Biologics Inc
  10. Boehringer Ingelheim International GmbH.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports